Definitive Healthcare (NASDAQ:DH) Updates FY 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 0.360-0.380 for the period, compared to the consensus EPS estimate of 0.380. The company issued revenue guidance of $255.0 million-$261.0 million, compared to the consensus revenue estimate of $266.3 million. Definitive Healthcare also updated its Q2 2024 guidance to 0.080-0.090 EPS.

Definitive Healthcare Stock Up 2.3 %

Shares of NASDAQ:DH traded up $0.12 during trading on Friday, hitting $5.29. 2,283,341 shares of the company’s stock traded hands, compared to its average volume of 661,623. The company has a 50-day moving average price of $7.61 and a 200-day moving average price of $8.27. The company has a current ratio of 2.31, a quick ratio of 2.31 and a debt-to-equity ratio of 0.20. The company has a market cap of $623.11 million, a price-to-earnings ratio of -2.90, a price-to-earnings-growth ratio of 6.12 and a beta of 1.41. Definitive Healthcare has a 52 week low of $4.38 and a 52 week high of $12.45.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Wednesday, February 28th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.02). The company had revenue of $65.93 million for the quarter, compared to analysts’ expectations of $66.01 million. Definitive Healthcare had a negative net margin of 80.40% and a positive return on equity of 0.43%. As a group, research analysts forecast that Definitive Healthcare will post 0.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft dropped their price target on Definitive Healthcare from $10.00 to $7.00 and set a hold rating for the company in a report on Thursday. Barclays decreased their price objective on shares of Definitive Healthcare from $11.00 to $7.00 and set an equal weight rating for the company in a report on Thursday. Morgan Stanley downgraded shares of Definitive Healthcare from an overweight rating to an equal weight rating and cut their price objective for the company from $11.50 to $9.00 in a research report on Wednesday. Stifel Nicolaus decreased their price target on shares of Definitive Healthcare from $11.00 to $9.50 and set a buy rating on the stock in a research note on Wednesday. Finally, Needham & Company LLC restated a hold rating on shares of Definitive Healthcare in a report on Wednesday. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $9.94.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.